Ferring Pharmaceuticals (U.S.) announced today that it has appointed Sophie Opdyke, Pharm.D., MBA as Vice President, General Manager, Oncology, effective immediately. She most recently served as Vice President, Immuno-Oncology Lead at Pfizer.
Opdyke’s role is Ferring’s first major executive appointment of 2019. She will be responsible for building the U.S. division, leading its day-to-day operations, and shaping its long-term strategic business plan. This includes leading the potential commercial launch of an investigational gene therapy for bladder cancer patients.
Opdyke has more than 20 years of experience in the pharmaceutical industry. Most recently at Pfizer, she led the development and execution of Pfizer’s strategy in Immuno-Oncology. Specifically, she oversaw all associated commercial activities from pre-clinical through launch for the company’s portfolio, including check point inhibitors, novel Immuno-Oncology targets and innovative technologies such as allogenic CAR-T and immune therapy-based vaccines. During her tenure, Opdyke was also instrumental in building and leading Pfizer’s Global Biosimilars organization, driving a core component of its biotherapeutics strategy.
“We’re delighted to welcome Sophie as the leader of our new oncology division as we prepare for a significant expansion of our presence in this area,” said Paul Navarre, CEO, Ferring Pharmaceuticals (U.S.). “Sophie’s depth of oncology experience and expertise are a significant asset to our U.S. leadership team.”
Opdyke holds a doctorate of Pharmacy and Master of Pharmaceutical Business from Université Paris Descartes and an MBA in finance and international business from Columbia Business School. She will report to Paul Navarre, CEO, Ferring Pharmaceuticals (U.S.).
Source: Ferring Pharmaceuticals Inc.
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.
Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.
Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”
